RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
1-Year Return
25.98%
This Quarter Return
-12.08%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$2.42B
AUM Growth
-$747M
(-24%)
Cap. Flow
-$195M
Cap. Flow
% of AUM
-8.07%
Top 10 Holdings %
Top 10 Hldgs %
25.87%
Holding
146
New
14
Increased
42
Reduced
23
Closed
13
Top Buys
| 1 |
Biogen
BIIB
|
$56.9M |
| 2 |
Centene
CNC
|
$30.9M |
| 3 |
Applied Therapeutics
APLT
|
$27M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$20.8M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$15M |
Top Sells
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$106M |
| 2 |
UnitedHealth
UNH
|
$72.6M |
| 3 |
Johnson & Johnson
JNJ
|
$59.3M |
| 4 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$35.2M |
| 5 |
MDCO
Medicines Co
MDCO
|
$26.1M |
Sector Composition
| 1 | Healthcare | 95.03% |
| 2 | Consumer Staples | 1.05% |
| 3 | Consumer Discretionary | 0.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
argenx
ARGX
$45.9B
| $32.6M | 1.35% |
247,500
| – | – |
|
27
BioMarin Pharmaceuticals
BMRN
$11.1B
| $32.1M | 1.33% |
380,000
+42,500
| +13% | +$3.59M |
|
28
Coherus Oncology, Inc. Common Stock
CHRS
$150M
| $31.6M | 1.31% |
1,950,000
| – | – |
|
|
EPZM
29
DELISTED
Epizyme, Inc
EPZM
| $30.3M | 1.25% |
1,955,000
-95,000
| -5% | -$1.47M |
|
30
Idexx Laboratories
IDXX
$51.4B
| $30.3M | 1.25% |
125,000
+4,800
| +4% | +$1.16M |
|
31
Pacira BioSciences
PCRX
$1.19B
| $30.2M | 1.25% |
900,000
-250,000
| -22% | -$8.38M |
|
32
Vertex Pharmaceuticals
VRTX
$102B
| $29.7M | 1.23% |
125,000
-78,000
| -38% | -$18.6M |
|
|
SGEN
33
DELISTED
Seagen Inc. Common Stock
SGEN
| $27.9M | 1.15% |
242,000
| – | – |
|
|
34
Applied Therapeutics
APLT
$68.2M
| $27.6M | 1.14% |
845,700
+825,385
| +4,063% | +$27M |
|
35
Ardelyx
ARDX
$1.57B
| $27.6M | 1.14% |
4,850,000
| – | – |
|
|
ONC
36
BeOne Medicines Ltd. American Depositary Shares
ONC
$37.6B
| $26.4M | 1.09% |
214,800
| – | – |
|
|
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $26.3M | 1.09% |
341,500
+41,500
| +14% | +$3.19M |
|
38
Amgen
AMGN
$153B
| $25.5M | 1.06% |
126,000
| – | – |
|
39
Freshpet
FRPT
$2.7B
| $25.4M | 1.05% |
397,500
+42,250
| +12% | +$2.7M |
|
40
Cigna
CI
$81.5B
| $25M | 1.03% |
141,000
+66,000
| +88% | +$11.7M |
|
41
Exact Sciences
EXAS
$10.2B
| $24.6M | 1.02% |
424,000
+4,000
| +1% | +$232K |
|
42
Ascendis Pharma
ASND
$12.5B
| $24M | 0.99% |
213,500
| – | – |
|
43
Assembly Biosciences
ASMB
$183M
| $22.2M | 0.92% |
125,000
| – | – |
|
44
Align Technology
ALGN
$10.1B
| $22.2M | 0.92% |
127,500
+16,600
| +15% | +$2.89M |
|
45
Collegium Pharmaceutical
COLL
$1.21B
| $19.2M | 0.79% |
1,175,000
-400,000
| -25% | -$6.53M |
|
46
uniQure
QURE
$985M
| $19M | 0.78% |
400,000
| – | – |
|
|
AMRN
47
Amarin Corp
AMRN
$317M
| $18.6M | 0.77% |
232,500
| – | – |
|
48
Incyte
INCY
$16.9B
| $18.3M | 0.76% |
250,000
| – | – |
|
49
Mirum Pharmaceuticals
MIRM
$3.82B
| $17.4M | 0.72% |
1,243,000
-2,000
| -0.2% | -$28K |
|
50
Aprea Therapeutics
APRE
$9.03M
| $17.4M | 0.72% |
25,000
-11,200
| -31% | -$7.79M |
|